GSE146402 Characterization of an Enzalutamide Resistant Primary Prostate Cancer Xenograft Derived from a Patient of West African Ancestry

Contributors : Brendon M Patierno ; Wen-Chi Foo ; Tyler Allen ; Jason A Somarelli ; Kathryn E Ware ; Santosh Gupta ; Sandra Wise ; John P Wise ; Xiaodi Qin ; Dadong Zhang ; Lingfan Xu ; Yanjing Li ; Xufeng Chen ; Brant A Inman ; Shannon J McCall ; Jiaoti Huang ; Rick A Kittles ; Kouros Owzar ; Simon Gregory ; Andrew J Armstrong ; Daniel J George ; Steven R Patierno ; David S Hsu ; Jennifer A FreedmanSeries Type : Expression profiling by high throughput sequencingOrganism : Homo sapiensHere we report the establishment and characterization of a Prostate Cancer Patient Derived Explant (PCPDX) from a patient of West African ancestry with metastatic castration resistant disease. The following data represents gene expression in a series of mice carrying this PCPDX and undergoing different treatment courses. Mice were treated for 10 weeks with either Enzalutamide, Cisplatin, or Docetaxel, or appropriate vehicle controls.
Source: GEO: Gene Expression Omnibus - Category: Genetics & Stem Cells Tags: Expression profiling by high throughput sequencing Homo sapiens Source Type: research

Related Links:

Source: Cancer Management and Research - Category: Cancer & Oncology Tags: Cancer Management and Research Source Type: research
tt Church Human group IIA secretory phospholipase A2 (hGIIA) promotes the proliferation of cancer cells, making it a compelling therapeutic target, but it is also significant in other inflammatory conditions. Consequently, suitable inhibitors of hGIIA have always been sought. The activation of phospholipases A2 and the catalysis of glycerophospholipid substrates generally leads to the release of fatty acids such as arachidonic acid (AA) and lysophospholipid, which are then converted to mediator compounds, including prostaglandins, leukotrienes, and the platelet-activating factor. However, this ability of hGIIA to p...
Source: Molecules - Category: Chemistry Authors: Tags: Review Source Type: research
PMID: 32976788 [PubMed - as supplied by publisher]
Source: Health Physics - Category: Physics Authors: Tags: Int J Radiat Oncol Biol Phys Source Type: research
Publication date: January 2021Source: Materials Science and Engineering: B, Volume 263Author(s): Nazire Altunkök, Özlem Biçen Ünlüer, Ebru Birlik Özkütük, Arzu Ersöz
Source: Materials Science and Engineering: B - Category: Materials Science Source Type: research
Publication date: November 2020Source: Urology Case Reports, Volume 33Author(s): Kazuki Okubo, Fumiko Hamabe, Kosuke Miyai, Makoto Isono, Hiroshi Shinmoto, Akinori Sato
Source: Urology Case Reports - Category: Urology & Nephrology Source Type: research
Authors: Lin Y, Zhong H, Sun B, Peng Y, Lu F, Chen M, Zhu M, Huang J Abstract Renal cell carcinoma (RCC) is one of the commonest urological tumors. The incidence of RCC ranks third among urological tumors, after prostate cancer and bladder tumors. However, the etiology of RCC remains unclear. Ubiquitin-specific protease 22 (USP22), a potential marker of cancer stem cells, is associated with the occurrence and progression of numerous tumors. However, the roles of USP22 in RCC have not yet been investigated. Survivin is a member of the inhibitor of apoptotic protein family involved in RCC progression. The present stu...
Source: Oncology Letters - Category: Cancer & Oncology Tags: Oncol Lett Source Type: research
emminki Asta Försti Familial clustering, twin concordance, and identification of high- and low-penetrance cancer predisposition variants support the idea that there are families that are at a high to moderate excess risk of cancer. To what extent there may be families that are protected from cancer is unknown. We wanted to test genetically whether cancer-free families share fewer breast, colorectal, and prostate cancer risk alleles than the population at large. We addressed this question by whole-genome sequencing (WGS) of 51 elderly cancer-free individuals whose numerous (ca. 1000) family members were found to ...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Article Source Type: research
In conclusion, we have confirmed the potential of fenofibrate for the metronomic treatment of drug‐resistant prostate tumors. However, docetaxel/fenofibrate‐induced selective expansion of hyper‐resistant CD44high SCL prostate cells and their “bulk” progenies prompts the microevolution of prostate tumor drug‐resistance. This process can limit the implementation of metabolic chemotherapy in prostate cancer treatment.© AlphaMed Press 2020Significance StatementFenofibrate has recently been shown to interfere with the drug ‐resistance of prostate tumor cells. Our current data confirmed that fenofibrat...
Source: Stem Cells - Category: Stem Cells Authors: Tags: Cancer Stem Cells Source Type: research
Prostate cancer is enumerated as one of the most prevalent cancers in men, with a mortality rate of 18%. Chemotherapy is considered as a common strategy for cancer treatment; however, toxic side effects and drug resistance associated with chemotherapy are major drawbacks with this approach. It is well known that a diet rich in flavonoids can reduce the incidence of many types of cancer in a significant manner, and it was proved that methoxy flavones have greater bioavailability compared to the nonmethylated ones. Calycopterin is a tetramethoxy flavone which was demonstrated to have anti-proliferative effects on colon, gas...
Source: Iranian Journal of Pharmaceutical Research - Category: Drugs & Pharmacology Source Type: research
ConclusionThe combination of niclosamide and temozolomide effectively decreased the stemness and invasive properties of GBM TSs, suggesting that this regimen may be therapeutically effective in treating patients with GBM.
Source: Journal of Cancer Research and Clinical Oncology - Category: Cancer & Oncology Source Type: research
More News: African Health | Cancer | Cancer & Oncology | Docetaxel | Genetics | Prostate Cancer | Taxotere